Focus: Millicent Pharma is a specialty pharmaceutical company headquartered in Dundalk, Ireland, focused on women's health with a concentrated portfolio in menopausal treatment. The company derives 99% of revenue from a single product, FEMRING.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Millicent Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's cash engine (99% of revenue) with no disclosed LOE date, representing existential risk if patent cliff materializes.
Help build intelligence for Millicent Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Millicent Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary product at peak lifecycle with patent exclusivity through March 2031; minimal revenue but regulatory stability.
Combination oral contraceptive with LOE approaching; appears to be legacy or deprioritized based on zero Part D spending visibility.
ANDA-approved generic contraceptive in post-LOE phase; faces generic competition with no disclosed revenue.
ANDA-approved generic contraceptive in post-LOE phase; competes in commodity market with declining economics.
Newest product (NDA) with growth designation and long patent tail (2041); only forward-looking asset but faces efficacy restrictions in obese populations.
1 discontinued, 2 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo